One To Watch

Cidara Therapeutics

Company Overview

A San Diego-based biotechnology company developing long-acting antifungal and antiviral drug conjugates, now acquired by Merck & Co in a landmark $9.2 billion deal that underscores the strategic value of its respiratory and anti-infective pipeline. Cidara built its platform around novel drug conjugate technology designed to address serious unmet needs in infectious disease, including invasive fungal infections and influenza. Its lead antifungal rezafungin and long-acting antiviral CD388 represent two distinct but complementary therapeutic bets. The Merck acquisition, completed in late 2025, validated Cidara's technology and positioned its assets within one of the industry's largest respiratory and anti-infective portfolios.

Headquarters and Global Presence

Cidara Therapeutics is headquartered in San Diego, California, the hub of its research and clinical development operations. Following the completed Merck acquisition, the company's programs are now being integrated into Merck's global infrastructure and expanding respiratory portfolio.

Founding and History

Cidara was founded in 2012 by a team of seasoned biotechnology executives and scientists, with Jeffrey Stein among the founding leadership. The company listed on Nasdaq under the ticker CDTX and built its pipeline around antifungal and antiviral drug conjugate technology over more than a decade. Rezafungin's commercial path was set in 2019 by a licence agreement with UK-based Mundipharma worth up to $568 million, covering ex-US/Japan rights; in June 2024 Cidara restructured the relationship via a divestiture and milestone-waiver to streamline costs ahead of late-stage execution. Merck & Co announced the $9.2 billion acquisition in November 2025, citing the strategic fit with its respiratory franchise ahead of Keytruda's 2028 patent cliff; the tender offer is expected to close in Q1 2026.

Therapy Areas and Focus

Cidara's primary focus spans invasive fungal infections and respiratory viral disease, two areas characterized by high mortality, limited treatment options, and growing resistance concerns. Invasive candidiasis and related fungal infections represent a serious unmet need in immunocompromised and critically ill patients, where existing azole and echinocandin therapies carry tolerability or dosing limitations. The antiviral program, centered on CD388, targets influenza, an indication where pandemic preparedness and prophylaxis represent substantial commercial and public health imperatives. Merck's acquisition specifically cited the respiratory portfolio fit, reflecting the strategic logic of combining Cidara's assets with Merck's existing respiratory infrastructure.

Technology Platforms and Modalities

Cidara's core platform is built around drug conjugate technology, applying conjugation chemistry to small-molecule anti-infectives to extend half-life, improve tissue distribution, and enable less frequent dosing. Rezafungin is an echinocandin antifungal optimized for once-weekly intravenous dosing, a significant differentiation from the daily dosing schedules of existing agents in its class. CD388 is a neuraminidase inhibitor conjugate designed for long-acting influenza prophylaxis and treatment, potentially enabling single-dose or seasonal dosing regimens. The platform's ability to translate established anti-infective mechanisms into improved dosing profiles is central to Cidara's value proposition and the rationale behind Merck's interest.

Key Pipeline and Programs

CD388 is Cidara's lead antiviral asset and a primary driver of Merck's acquisition interest. It is a long-acting neuraminidase inhibitor drug conjugate targeting influenza A and B, designed to provide extended prophylactic and therapeutic protection from a single or infrequent dose. CD388 entered clinical development and has been evaluated in Phase I and Phase II trials; its broad pandemic preparedness potential is central to Merck's expanding respiratory strategy.

Rezafungin is an echinocandin antifungal conjugate developed for invasive candidiasis and candidemia. The asset was partnered with Mundipharma in June 2024 in a deal worth up to $568 million to Cidara, covering commercialization rights outside the United States. Rezafungin's once-weekly dosing schedule distinguishes it within the echinocandin class, where standard-of-care agents require daily infusions, and the asset has progressed through Phase III evaluation.

Recent Developments

In June 2024, Cidara announced a licensing and commercialization partnership with Mundipharma for rezafungin, with total potential value of $568 million; the news drove an 79% single-day surge in Cidara's share price. Merck & Co announced the acquisition of Cidara Therapeutics in November 2025 in a cash deal valued at approximately $9.2 billion, with the tender offer expected to close in Q1 2026. Merck described the transaction as strengthening and complementing its expanding respiratory portfolio, with CD388 identified as a key strategic asset. As of early 2026, integration of Cidara's pipeline into Merck's operations is underway, with Merck reporting that acquisition costs had a near-term impact on its financials, offset by continued Keytruda growth.

Key Personnel

Jeffrey Stein serves as President and Chief Executive Officer and is among Cidara's founding team, having led the company from inception through its Nasdaq listing and the Merck acquisition. Dan Burgess serves as Chairperson of the Board, providing governance oversight through the company's strategic transactions. Nicole Davarpanah serves as Senior Vice President, Translational Research and Development, leading the scientific bridge between platform innovation and clinical execution.

Strategic Partnerships

The June 2024 licensing deal with Mundipharma — covering rezafungin commercialization rights outside the United States for up to $568 million — was Cidara's most significant pre-acquisition partnership and demonstrated broad international commercial appetite for its antifungal program. The $9.2 billion acquisition by Merck & Co, completed in late 2025, represents the definitive strategic transaction, absorbing Cidara's full pipeline and platform into Merck's respiratory and anti-infective portfolios.

FAQ Section

Merck explicitly cited the strategic fit with its expanding respiratory portfolio as the rationale, with CD388 — Cidara's long-acting influenza antiviral — seen as a high-value asset for pandemic preparedness and seasonal prophylaxis. The acquisition also came as Merck prepares for the 2028 loss of patent exclusivity on Keytruda, its blockbuster cancer drug, and needed pipeline reinforcement. At $9.2 billion, the deal reflects both the commercial potential of CD388 and the platform's ability to generate differentiated anti-infective candidates.

CD388 is a neuraminidase inhibitor drug conjugate engineered for extended half-life, enabling single-dose or infrequent dosing for influenza prophylaxis and treatment. Neuraminidase inhibition prevents viral release from host cells, blocking propagation of influenza A and B strains. The long-acting profile addresses a key limitation of existing agents like oseltamivir, which require daily dosing and have narrow prophylactic windows, making CD388 particularly relevant for pandemic preparedness scenarios.

Cidara applies conjugation chemistry to established anti-infective pharmacophores — echinocandins and neuraminidase inhibitors — to dramatically extend their pharmacokinetic profiles without sacrificing the proven mechanisms of action. Rezafungin achieves once-weekly intravenous dosing versus the daily schedule required for standard echinocandins like caspofungin, which matters significantly for outpatient and step-down therapy settings. This approach de-risks the biology while innovating on delivery, a combination that attracted both Mundipharma's commercial interest and Merck's acquisition premium.

Rezafungin is an echinocandin antifungal optimized for once-weekly intravenous dosing, targeting invasive candidiasis and candidemia — life-threatening fungal infections with high mortality in hospitalized and immunocompromised patients. The asset progressed through Phase III clinical evaluation and attracted a licensing partnership with UK-based Mundipharma in June 2024, covering ex-US rights for up to $568 million. Rezafungin's differentiated dosing schedule relative to daily echinocandins positions it as a meaningful improvement for patients requiring prolonged antifungal therapy.

Cidara's pipeline is anchored in two therapeutic areas: invasive fungal infections and respiratory viral disease, specifically influenza. Both represent serious, underserved infection categories where current treatment options are constrained by daily dosing, tolerability issues, or limited prophylactic utility. Merck's acquisition integrates these programs into a broader respiratory and anti-infective strategy, suggesting the pipeline will be further developed within that commercial and scientific context going forward.

Rezafungin completed Phase III clinical development and is in the commercialization and licensing phase, with Mundipharma holding ex-US rights. CD388 advanced through Phase I and Phase II clinical trials prior to the Merck acquisition, with its long-acting antiviral profile driving substantial investor and acquirer interest. Integration into Merck's development infrastructure is expected to accelerate CD388's path toward late-stage trials, with pandemic preparedness and seasonal influenza applications as the primary near-term development targets.

The principal watchpoints as Cidara's programs transition into Merck include:

CD388 Phase II/III progression: trial design, endpoints, and data readouts for influenza prophylaxis will define the asset's commercial trajectory under Merck's stewardship.
Rezafungin ex-US commercialization: Mundipharma's launch execution and market uptake outside the US represent a key near-term revenue catalyst.
Integration execution risk: absorbing Cidara's platform and talent into Merck's organization carries execution risk, particularly for early-stage discovery programs.
Merck's post-Keytruda cliff positioning: the $9.2 billion price tag creates expectations; underwhelming CD388 data or commercial delays could weigh on Merck's pipeline narrative heading into 2028.

Want to Update your Company's Profile?